Fortrea Holdings/$FTRE

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About Fortrea Holdings

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Ticker

$FTRE
Primary listing

Industry

Life Sciences Tools & Services

Employees

15,000

ISIN

US34965K1079

Fortrea Holdings Metrics

BasicAdvanced
$493M
-
-$8.81
-
-

What the Analysts think about Fortrea Holdings

Analyst ratings (Buy, Hold, Sell) for Fortrea Holdings stock.

Bulls say / Bears say

Fortrea's fourth-quarter 2024 book-to-bill ratio was 1.35x, indicating strong demand and potential revenue growth. (Fortrea Reports Fourth Quarter and Full-Year 2024 Results)
Activist investor Keith Meister projects a 42% upside for Fortrea's stock, suggesting confidence in the company's growth prospects. (Corvex founder Meister sees big upside for stocks already targeted by others)
Fortrea's transition from its former parent company has been completed, positioning it for independent strategic initiatives and potential operational efficiencies. (Fortrea Reports Fourth Quarter and Full-Year 2024 Results)
Fortrea reported a GAAP net loss of $271.5 million for the full year 2024, raising concerns about its profitability. (Fortrea Reports Fourth Quarter and Full-Year 2024 Results)
The company's 2025 revenue guidance of $2.45 to $2.55 billion reflects a potential decline from 2024 revenues, indicating possible challenges in maintaining growth. (Fortrea Reports Fourth Quarter and Full-Year 2024 Results)
Fortrea's gross debt stood at $1.142 billion as of December 31, 2024, which may limit financial flexibility and increase interest expenses. (Fortrea Reports Fourth Quarter and Full-Year 2024 Results)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Fortrea Holdings Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Fortrea Holdings Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FTRE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs